Columbia’s Dian Yang is placing CRISPR-based molecular recorders into cancer cells to eavesdrop on cancer evolution and pinpoint when and how cells metastasize.
Misinformation and outdated beliefs about screening tests, treatment options, and effects on sexual health continue to cloud understanding about this disease.
The Columbia community gathered in the Hudson Valley for the eighth annual Velocity: Columbia’s Ride to End Cancer. This year’s event raised more than $1 million and attracted nearly 600 participants.
Columbia researchers have engineered bacteria as personalized cancer vaccines that activate the immune system to specifically seek out and destroy cancer cells.
New guidelines encourage initial screening for colorectal cancer at 45 instead of 50, because younger people are increasingly being diagnosed with the disease, says Columbia's James Church, MD.
Opinions vary about how to treat DCIS (ductal carcinoma in situ), but a new study suggests the optimal treatment for most women with this non-invasive breast cancer is surgery plus radiation.
Results from a phase 2 clinical trial led by Columbia cancer researchers suggest that a combination of two drugs has potential to improve treatment of uterine leiomyosarcoma.
Larisa Geskin's first lobbying success led New York state to prohibit indoor tanning for children. Now she's urging Medicaid to help low-income families access sunscreen.
Many women and their physicians stick to annual Pap and HPV tests, Columbia researchers have found, despite new guidelines recommending less frequent cervical cancer screening.
Columbia cancer researchers are testing a new chemotherapy regimen for patients with an invasive form of bladder cancer who have limited options beyond radical surgery if initial treatment fails.
Newly identified immune cells infiltrate tumors in patients with localized kidney cancer and may be driving the cancer’s recurrence, Columbia researchers have found.
Scientists have found that many esophageal cancers turn on ancient viral DNA embedded in our genome, a finding that could lead to improvements in immunotherapy.